Insulin Strategies for Primary Care Providers-Reference-Cited by-同舟云学术

Insulin Strategies for Primary Care Providers

Published:2002-01-01 Issue:1 Volume:20 Page:11-17
ISSN:0891-8929
Container-title:Clinical Diabetes
language:en
Short-container-title:

Author:

Herbst Karen L.,Hirsch Irl B.

Abstract

IN BRIEF Primary care providers take care of the majority of patients with diabetes in the United States. The introduction of new insulin analogs over the past few years should help primary practitioners and their patients with diabetes achieve physiological insulin replacement and near-normal glucose levels. This article reviews currently available insulins and replacement of insulin in a physiological manner for patients with type 1 or type 2 diabetes and provides examples of patients for whom insulin dosages changed over time.

Publisher

American Diabetes Association

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/clinical/article-pdf/20/1/11/497747/0011.pdf

Reference33 articles.

1. Hiss RG: Barriers to care in non-insulin-dependent diabetes mellitus: the Michigan experience. Arch Intern Med 124:146–148, 1996

2. Janes GR: Ambulatory medical care for diabetes. In Diabetes in America. 2nd ed. National Diabetes Data Group, Eds. Bethesda, Md., National Institutes of Health, National Institute of Diabetes and Digestive Kidney Diseases (NIH publication No. 95-1468), 1995, p. 541–552

3. Mazze RS, Donnell DE, Strock E, Peterson K, McClave CR, Meszaros JF, Leigh C, Owens LW, Deeb LC, Peterson A, Kummer M: Staged diabetes management toward an integrated model of diabetes care. Diabetes Care 17 (Suppl. 1):56–66, 1994

4. Harris MI: Testing for blood glucose by office-based physicians in the U.S. Diabetes Care 13:419–426, 1990

5. Tabak AG, Tamas G, Zgibor J, Wilson R, Becker D, Kerenyi Z, Orchard TJ: Targets and reality: a comparison of health care indicators in the U.S. (Pittsburgh Epidemiology of Diabetes Complications Study) and Hungary (DiabCare Hungary). Diabetes Care 23:1284–1289, 2000

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus H umalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early‐phase study;Diabetes, Obesity and Metabolism;2021-10-27

2. Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double‐blind meal test early‐phase study;Diabetes, Obesity and Metabolism;2021-10-24

3. Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects;Clinical Therapeutics;2020-09

4. Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects;Diabetes Therapy;2020-06-13

5. Ultra‐Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog ® in Japanese patients with type 1 diabetes;Journal of Diabetes Investigation;2020-01-07